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Background: The additional benefit of lifestyle interventions in patients receiving cardioprotective drug treatment
to improve cardiovascular risk profile is not fully established.
The objective was to evaluate the effectiveness of a target-driven multidisciplinary structured lifestyle intervention
programme of 6 months duration aimed at maximum reduction of cardiovascular risk factors in patients with
cardiovascular disease (CVD) compared with usual care.
Methods: A single centre, two arm, parallel group randomised controlled trial was performed. Patients with stable
established CVD and at least one lifestyle-related risk factor were recruited from the vascular and cardiology
outpatient departments of the university hospital. Blocked randomisation was used to allocate patients to the
intervention (n = 71) or control group (n = 75) using an on-site computer system combined with allocations in
computer-generated tables of random numbers kept in a locked computer file. The intervention group received the
comprehensive lifestyle intervention offered in a specialised outpatient clinic in addition to usual care. The control
group continued to receive usual care. Outcome measures were the lifestyle-related cardiovascular risk factors:
smoking, physical activity, physical fitness, diet, blood pressure, plasma total/HDL/LDL cholesterol concentrations,
BMI, waist circumference, and changes in medication.
Results: The intervention led to increased physical activity/fitness levels and an improved cardiovascular risk factor
profile (reduced BMI and waist circumference). In this setting, cardiovascular risk management for blood pressure
and lipid levels by prophylactic treatment for CVD in usual care was already close to optimal as reflected in baseline
levels. There was no significant improvement in any other risk factor.
Conclusions: Even in CVD patients receiving good clinical care and using cardioprotective drug treatment, a
comprehensive lifestyle intervention had a beneficial effect on some cardiovascular risk factors. In the present era of
cardiovascular therapy and with the increasing numbers of overweight and physically inactive patients, this study
confirms the importance of risk factor control through lifestyle modification as a supplement to more intensified
drug treatment in patients with CVD.
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Cardiovascular disease (CVD) is a leading cause of death
and loss of disability-adjusted life-years worldwide [1,2].
Because drug therapy is currently part of routine cardio-
vascular risk management, most patients with estab-
lished CVD use cardiovascular protective medication
and their cardiovascular risk profile has most likely
improved.
There is strong evidence that lifestyle programmes
have a beneficial effect on recurrent cardiovascular
events [3-5]. Therefore, guidelines on secondary preven-
tion and treatment for CVD emphasise the importance
of lifestyle intervention [5-7]. However, the additional
benefit of such interventions in a era in which most
patients receive optimal treatment for hypertension, ab-
normal lipid profile, and disturbances in haemostatis
and fibrinolysis is scarce [8,9].
The EUROASPIRE Surveys (investigating cardiovascu-
lar patients in nine countries, including the Netherlands)
showed that cardiovascular disease prevention in routine
clinical practice is inadequate. Lifestyle-related risk fac-
tors have deteriorated over time in these countries, and
the number of overweight/obese persons with CVD is
increasing [10].
Consequently there is an increasing interest in com-
prehensive multidisciplinary lifestyle programmes for
CVD patients with multiple modifiable risk factors, who
are unable to change their unhealthy lifestyle on their
own [11]. However, medical staff are insufficiently
trained and/or equipped to target lifestyle with such
comprehensive programmes.
The EUROACTION study group showed that stan-
dards of preventive care in general hospital and general
practices can be improved by a comprehensive approach
that addresses all aspects of lifestyle, risk factor manage-
ment, and cardioprotective drug treatments. They con-
cluded that there was a need for local preventive
cardiology programmes adapted to individual countries,
which are accessible by all hospitals and general prac-
tices caring for coronary and high-risk patients [9].
Such a comprehensive multidisciplinary structured
intervention aimed at lifestyle modification and max-
imum reduction of cardiovascular risk factors was
developed in the Netherlands. This comprehensive
programme (of 6 months duration) was offered in an
outpatient clinic and aimed at improvement of physical
activity levels, dietary habits and smoking cessation; acardiologist adjusted cardiovascular medication after
3 months if necessary. Preliminary results from a non
controlled study showed promising results [12].
To improve care in preventive cardiology, the add-
itional benefit of risk factor control through lifestyle
intervention (in addition to regular drug treatment) is
important. Therefore the aim of the present study was to
evaluate the effectiveness of an intensive multidisciplin-
ary structured intervention of six months duration aimed
at lifestyle modification and targeted risk factor improve-
ment in addition to usual care in patients with CVD on
cardiovascular risk factors compared to usual care alone.
Methods
A single centre, two arm, parallel group randomised
controlled trial (RCT) with a 6 month follow-up was
conducted (ISRCTN 69776211, www.controlled-trials.
com). The protocol was approved by the Medical Ethics
Committee of the VU University Medical Center Am-
sterdam (VUmc). There were no changes to methods
after trial commencement.
Patients were asked to participate in the study after re-
ceiving oral and written information, and were given
time to reflect on their participation in the study before
giving written informed consent. The study followed the
recommendations of the Declaration of Helsinki II [13].
Data in this paper were reported in compliance with the
Consolidated Standards of Reporting Trials (CONSORT)
guidelines extension for parallel group randomised trials
[14].
Inclusion and exclusion criteria
Patients with stable established CVD were recruited
from the vascular and cardiology outpatient departments
of the VUmc. CVD was defined as coronary heart dis-
ease (CHD), angina pectoris, myocardial infarction, per-
ipheral vascular disease, cerebrovascular accident,
transient ischaemic attack, or having received surgical
interventions such as a coronary artery bypass graft or
percutaneous coronary intervention.
Eligible patients aged 18–75 years had to be diagnosed
with CVD by a physician and had to have at least one of
the following cardiovascular risk factors: hypertension
(high blood pressure and/or use of antihypertensive
medication), dislipidaemia, hypercholesterolaemia, or
diabetes mellitus, and at least one lifestyle-related risk
factor: overweight or obese indicated by a body mass
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(defined as not meeting the Dutch Physical Activity
guideline) [15].
Excluded were patients with unstable CVD, a systolic
blood pressure ≥ 180 mmHg and/or a diastolic blood
pressure ≥ 110 mmHg, and patients with diabetes and a
glycated hemoglobin (HbA1c) level ≥ 10.0%. Comorbidity
had to be stable and be judged by the referring physician
as no contraindication to engage in physical exercise. Fi-
nally, patients should be able to climb stairs and ad-
equately communicate in the Dutch language.
Eligible patients were informed by their medical
specialist and invited to participate. They received an
information package containing a letter of invitation,
a study leaflet, a questionnaire, and a return envelope.
Additional potentially eligible patients were identified
from the database of the departments of cardiology
and vascular surgery. These patients were contacted
by telephone to verify their eligibility shortly after
they received the information package by mail. If the
patient was willing to participate their specialist and
general practitioner (GP) were informed. Written
informed consent was obtained from all participants at
the time of enrolment.
Randomisation and blinding
An independent researcher (not involved in the selec-
tion/treatment of patients) prepared the randomisation
with a computer-generated digital table of random num-
bers in blocks of 8. To ensure blinding of treatment allo-
cation, a research nurse randomly assigned patients to
either the intervention or control group using an on-site
computer system combined with allocations kept in a
locked computer file.
Caregivers could not be blinded for treatment alloca-
tion; however, apart from evaluation of physical capacity
(using strict objective criteria and standard protocols)
they were not involved in the assessment of outcome
measurements. Also, the research nurse performing the
physical measurements could not be blinded for treat-
ment allocation; however, she was not involved in the
intervention and this could not have affected any of the
more objective outcome measurements e.g. laboratory
results. The principal investigator was blinded for the al-
location of the intervention when performing the data
analysis. For obvious reasons, patients could not be
blinded for treatment allocation. Patients allocated to
the control group were informed that they could partici-
pate in the intervention after the study had finished.
Interventions
The intervention group received the comprehensive
multidisciplinary structured lifestyle intervention, in
addition to usual care.Intervention programme
The lifestyle programme was developed by a team con-
sisting of a physiotherapist, sport physician, cardiologist,
psychologist, nutritionist and internist [12]. The
programme was offered in a specialised outpatient clinic
and was targeted at optimal cardiovascular risk factor re-
duction by dietary modification, physical exercise and
smoking cessation. If necessary, additional medical ther-
apy could be provided after the first 3 months, targeted
at optimal risk factor reduction.
Prior to start of the lifestyle programme, a diagnostic
programme took place. A standardised computer ques-
tionnaire on medical history, symptoms, lifestyle and
medication formed the basis of a detailed medical his-
tory. Standard measurements of body height/weight and
blood pressure were made. Blood samples were taken
for determination of total/HDL/LDL cholesterol levels.
Finally, a physician performed a physical examination
and maximal work rate was measured on a bicycle erg-
ometer. Patients were given the results by the physician,
and a written medical report focusing on risk factors
and risk behaviour was handed to the patient and mailed
to the referring physician. The same diagnostic programme
was repeated 6 months later.
The lifestyle programme lasted 6 months. In short, the
first 3 months focused on intensive group-based (max-
imum 12 persons) physical training, education and
counselling. The exercise programme was offered twice
weekly, consisting of an individualised exercise session
of 1 h (based on aerobic threshold and maximal heart
rate) followed by a relaxation session of 30 min, giving a
total of 22 sessions in 3 months. During this period a
group counselling programme consisting of 7 sessions
focusing on risk factors, physical activity, diet, motiv-
ation, stress management and training modalities was
supervised by one of the specialised team members.
During the last session, patients were instructed to de-
sign a personal training programme to incorporate a
long-term maintenance regimen in daily life using sup-
port systems such as a gymnasium or other facilities of
their choice.
In the second 3 months, the aim was to implement
lifestyle changes in everyday life, supported by a
monthly exercise session led by the physiotherapist. All
patients had to be referred by a physician to be eli-
gible for compensation from their health insurance
company, leaving a relatively small financial contribu-
tion to be made by patients allocated to the lifestyle
programme.
Smokers were encouraged to quit and offered assistance
from a psychologist who conducted an individually-tailored
psychosocial intervention. Patients had to set a target date
to stop smoking, and follow-up visits were scheduled to
monitor progress. A nutritionist informed patients about a
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mixed low-fat and Mediterranean regimen [16,17].
Control group
Usual care or conventional risk-factor treatment was
provided by the GP or medical specialist according to
the Dutch guidelines for the care of patients with CVD
[7,18]. In the Netherlands, patients with CVD are treated
with blood pressure-lowering medication, lipid-lowering
medication (e.g. statins), anticoagulants, ACE inhibitors,
beta-blockers, antiplatelet therapy, and antithrombotics.
In addition, patients with diabetes receive oral glucose-
lowering medication and/or insulin. Usual healthy life-
style advice is given.
Compliance and co-interventions
The number of sessions attended was registered, and
compliance was considered adequate if at least 15 of the
22 exercise sessions (70%) were attended. No patients
were restricted in their options to obtain additional
health care. During the intervention period and follow-
up, co-interventions were registered and evaluated in
both groups.
Outcome assessment
The primary outcome measures were the lifestyle-related
cardiovascular risk factors (smoking status, exercise and
eating habits), and other cardiovascular risk factors in-
cluding weight, BMI, waist circumference, diastolic/
systolic blood pressure, total/HDL/LDL cholesterol,
physical fitness and changes in medication. Secondary
outcome measures were estimated risk of cardiovascu-
lar morbidity, total mortality, and quality of life.
Data collection
Data on physical measurements and self-administered
questionnaires were collected at baseline, and at 3 and
6-months follow-up. A research nurse performed the
physical measurements and collected the questionnaires.
Anthropometric measurements and laboratory tests
Physical measurements were made according to a stan-
dardised protocol. Individuals who did not attend the 3-
month follow-up were contacted twice (by mail and by
telephone). Those who did not withdraw from the study
were considered ‘not available’ for that follow-up and
were contacted for the next follow-up.
Body weight/height were measured to calculate BMI.
Height was measured to the nearest 0.1 cm without
shoes, and weight to the nearest 0.5 kg wearing under-
wear and no shoes. Persons with a BMI ≥ 25 and < 30
were considered overweight, those with a BMI of ≥ 30
were considered obese. Waist circumference was mea-
sured following the WHO criteria [19]. Systolic/diastolicblood pressure was measured in a standard way (Omron
705IT): the first measurement was made after 5 min rest
in sitting position and the mean of the three measure-
ments per visit was used.
Blood and urine samples for determination of total/
HDL/LDL cholesterol, glucose, and Hb1Ac were col-
lected after overnight fast.
Maximal work rate was measured on a bicycle ergom-
eter and the corresponding metabolic equivalent of task
(MET) scores were calculated [20].
Questionnaires
On three occasions (with a 3-month interval in between)
patients completed a self-administered questionnaire on
(family) medical history, lifestyle, depression, general
health status and health-related quality of life (HRQL).
Questionnaires were either given at the recruitment visit,
or sent home with the request to bring the completed
questionnaire to the next visit. Additional information
on medical history was retrieved from the patient’s med-
ical file.
At baseline, various prognostic measures were col-
lected to evaluate whether randomisation successfully
resulted in two groups with comparable prognosis,
and (if necessary) to adjust for baseline differences in
the analyses. Sociodemographic information included
age, sex, level of education, ethnicity and working
status.
The validated Short Questionnaire to Assess
Health-enhancing physical activity (SQUASH) ques-
tionnaire was used to assess self-reported levels of
physical activity [21]. Patients were asked to refer to
an average week in the past few months. Using the
Ainsworth compendium of physical activities [22], ac-
tivities were assigned a MET value. One MET is
defined as the energy expenditure for sitting quietly.
Based on the Dutch physical activity guideline [15],
activities were subdivided for adults and older adults
(up to age 55 and older) respectively into three in-
tensity categories. The total amount of minutes per
day that a patient was performing light (2–4MET),
moderate (age > 18–55 years: 4–6.5 MET; age
>55 years: 4–5 MET), or heavy physical activity (age
18–55 years ≥ 6.5 MET; age >55 years: ≥ 5 MET) was
calculated (MET = unit of metabolic equivalent, which
is the ratio of the energy cost of a given activity to
resting metabolic rate and was derived from pub-
lished tables [22].
Eating behaviour was assessed by a Dutch Food Fre-
quency Questionnaire (DFFQ) [23]. A smoker was
defined as someone who reported to smoke at least one
cigarette, cigar or pipe in the past week. Abstinence was
assessed by self-report; the outcome is dichotomous (ab-
stinent versus smoking).
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has a good reliability and validity [24]. It yields a physical
component and mental component; both scores range
from 0 to 100, with higher scores representing better
health. Level of depressive symptoms was measured
using the 20-item Centre for Epidemiologic Studies De-
pression Scale (CES-D) [25]. Total scores range from 0
to 60. A cut-off score of ≥ 16 was used to identify
respondents with a clinically significant level of depres-
sion [26].
HRQL is considered to be an integral part of out-
come measures in preventive cardiology [27]. The
MacNew is a disease-specific instrument for measuring
HRQL in cardiac patients; it is valid and reliable to
measure HRQL of patients with CHD [28-30]. Scores
range from 1–7, with higher scores indicating a better
HRQL [28]. The VascuQol is a disease-specific HRQL
instrument for peripheral arterial disease. Patients’
responses are converted to a scale ranging from 1
(worst possible score) to 7 (best possible score) [31].
A total score is calculated, with a higher score indicat-
ing a better HRQL. The 10-year risk of developing
cardiovascular events and mortality was estimated
using the Copenhagen Risk Score (PRECARD risk
profile) [32].
Statistical analysis
In this study we aimed to study the cost-effectiveness.
We had based our sample size calculation on finding a
difference in total costs between the two groups of
15%. However, we had to stop recruitment prematurely
due to a lack of financial resources. During the recruit-
ment period there was a change in insurance policy.
The costs of the intervention were no longer reim-
bursed for patients. In the end we had 71 patients in
the intervention group and 75 in the control group.
The primary outcome measure used in the power cal-
culation of this study was the Copenhagen Risk Score
(CRS). We used a European risk calculation pro-
gramme named PRECARD to calculate the absolute
risk of CVD. The CRS is based on age, gender, BMI,
history of CVD, Diabetes Mellitus, smoking status, sys-
tolic blood pressure, HDL and total cholesterol levels.
A post-hoc power calculation showed that in order to
detect a difference in change of 5% in absolute esti-
mated CVD risk calculated by the CRS with a standard
deviation of 10%, with statistical significance (alpha =
0.05) and sufficient power (1-beta = 0.80) we needed 62
patients in each group. With a possible drop-out rate
of 15% the number of participants to be randomised
was 72 per group.
The effects of the intervention on outcome measures
at 3 and 6 months follow-up were analysed according to
the intention-to-treat principle [33], including allsubjects regardless of whether or not they actually
received the complete intervention. The analysis was
conducted with all available respondents at the time of
follow-up; non-response analyses were conducted to
evaluate whether drop-out during the first or second
follow-up period was associated with health status or
intervention status. The effects of the intervention on
the continuous health measures were evaluated with lin-
ear regression models. All regression models were
adjusted for sex and age, and included the baseline value
of the health measure of interest. Resulting regression
coefficients can be interpreted as the difference in pa-
tient outcomes between both groups at a certain follow-
up period corrected for the difference at baseline. The
effects of the intervention on the dichotomous health
measures were analysed by logistic regression. In a sensi-
tivity analysis, the multiple imputations technique was
used for missing data.
Analyses were performed with the statistical package
SPSS.Results
Participants
Between September 2005 and February 2007, 146 parti-
cipants were enrolled in the study. Figure 1 presents the
CONSORT diagram [34] of the flow of participants
through the phases of the trial. At baseline, 875 patients
were invited to participate of which 146 (17%) gave writ-
ten consent and completed baseline measurements.
Patients with a low level of education and retired
patients were less likely to participate. Motives and bar-
riers underlying the decision to participate or not were
explored and reported elsewhere [35].
A total of 71 patients were assigned to the interven-
tion programme and 75 to the usual care group; 82%
of the patients remained in the study during the 6-
month follow-up. Analyses showed no selective loss to
follow-up. Table 1 presents the baseline characteristics
of the study population. Baseline characteristics of the
outcome measures are presented in Tables 2, 3, 4 and
5. The randomisation was successful in creating study
groups with largely similar baseline values, including
current and past health conditions. Therefore, adjust-
ment was made only for the baseline values of the out-
come measures sex and age, and not for the other
prognostic variables. Smoking status showed a differ-
ence at baseline and was corrected for in the analyses
when necessary.Compliance
Compliance with the programme was good; on average
18 (range 2–22) of the 22 (80%) physical exercise ses-
sions were attended. One person stopped after two
Eligible to participate (n= 875)
Excluded (n= 729)
Declined to participate (n= 729)
Analysed at 3 months (n= 63) and 
at 6 months (n=59)
Lost to follow-up at 3 months (n= 1) and 
at 6 months (n=3)
Reasons for loss to follow-up:
Discontinued intervention because felt
too tired (n= 1)
Lost interest and lack of time (n= 3)
Allocated to intervention (n= 71)
Received allocated intervention (n= 63)
Did not receive allocated intervention (n= 8)
Reasons:
Preferred usual care group (n= 1)
Withdrawn, lost interest and time (n= 4)
Back operation (n= 1)
CVI prior to start programme (n= 1)
Gastric haemorrhage (n= 1)
Lost to follow-up at 3 months (n= 12) and  
at 6 months (n=3)
Reasons for loss to follow-up: 
Lost interest and lack of time (n= 12)
Mental health problems (n= 1)
Preferred intervention group (n= 2)
Allocated to and received usual care (n= 75)
Analysed at 3 months (n= 63) and 
at 6 months (n=60)
Allocation
Analysis
Follow-Up
Randomised (n= 146)
Enrollment
Figure 1 Flow diagram of the progress of participants through the trial.
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vacation.
Effect on prescribed medication
At baseline all patients in both groups received medication
for CVD. Table 2 shows that the prescribed medication
was almost identical in the two groups during follow-up.Most patients received aspirin, beta-blockers and sta-
tins. Overall, during the 6-month follow-up, changes in
prescribed medication were made in 35.6% (n = 21) of
the intervention group and in 30.0% (n = 18, including
additional gastro-medication in 1 patient) of the control
group. There were no intergroup differences for the use
of any specific drug.
Table 1 Baseline characteristics of the study population
(n =146)
Intervention
n= 71
Control
n =75
Sociodemographic characteristics
Mean age, years 60.4 (13.1) 59.6 (8.4)
Gender male, n (%) 60 (84.5) 53 (70.7)
Education Lower education, n (%) 20 (28.6) 27 (37.0)
Intermediate education, n (%) 32 (45.7) 27 (37.0)
Higher education, n (%) 18 (25.7) 19 (26.0)
Marital or cohabitation status, n (%) 49 (69.0) 54 (72.0)
Working status: Paid job, n (%) 23 (32.4) 28 (37.3)
Ethnic minority, n (%) 8 (11.3) 12 (16.0)
Prognostic factors
Clinical characteristics of CVD
Cardiology patients, n (%) 60 (84.5) 63 (84.0)
NYHA I a 34 (47.9) 30 (40.0)
NYHA II a 24 (33.8) 30 (40.0)
NYHA III a 2 (2.8) 3 (4.0)
Vascular patients, n (%) 11 (15.5) 12 (16.0)
PAV I b 4 (5.6) 5 (6.7)
PAV II b 6 (8.5) 6 (8.0)
PAV III b 1 (1.4) 0 (0.0)
Angina Pectoris, n (%) 6 (8.5%) 5 (6.7)
Myocardial Infarction, n (%) 58 (81.7) 62 (82.7)
Coronary Artery Bypass Graft, n (%) 26 (36.6) 23 (30.7)
Percutaneous Coronary
Intervention, n (%)
31 (43.7) 38 (50.7)
Cerebrovascular Accident, n (%) 9 (12.7) 4 (5.3)
Comorbidity Diabetes Mellitus, n (%) 18 (25.4) 14 (18.7)
At risk for depression
(CES-D score≥ 16), n (%)
19 (26.8) 20 (26.7)
Family history of CVD 31 (43.7) 34 (45.3)
Numbers are mean (SD) unless stated otherwise.
CVD= cardiovascular disease; aNYHA category among cardiology patients;
bPAV category among vascular patients.
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Lifestyle-related cardiovascular risk factors
Table 3 shows the effect of the intervention on lifestyle
measures. The intervention group showed a significant
increase in physical activity level per day compared with
the control group. There were no important differences
in eating behaviour. After 6 months the intervention
group was found to consume 0.5 more servings of
breakfast per week than participants receiving usual care
(p < 0.1). Favourable fat use was similar in both groups.
Smokers in the intervention and control group had
smoked for (mean) 29.5 (SD 18.3) years and 33.0 (16.3)
years, respectively. The intervention was not successful
in changing smoking behaviour. In the interventiongroup 2 of the 10 smokers for whom there was a follow-
up available had quit smoking, while one non-smoker
started smoking again. In the control group none of the
smokers quit smoking.
Other modifiable cardiovascular risk factors
Table 4 presents the effects on other primary outcome
measures. Weight, BMI and waist circumference showed
a significant decrease in the intervention group com-
pared with the control group. There were no significant
differences at 3 and 6 months in mean blood pressure
and total/HDL/LDL levels. There was a significant in-
crease in maximal work rate in the intervention group
compared with the control group (6.9 Watt [95% CI:
0.9/13.0]; 0.3 METS [95% CI: 0.1/0.5]). These results
remained largely the same after additional adjustment
for smoking status.
Effect of the intervention on secondary outcome measures
Table 5 presents the effects of the programme on sec-
ondary outcome measures. There was no significant dif-
ference in estimated 10-year risk for cardiovascular
morbidity and mortality, general health, and HRQL be-
tween the two groups.
Sensitivity analysis
In the sensitivity analyses no effect of the intervention
was found for specific subgroups of patients who
reported depression. Multiple imputations for missing
data showed similar effects of the intervention on all
outcome measures.
Discussion
This study shows that even in intensely pharmacologically-
treated CVD patients who received cardioprotective drug
treatment, a comprehensive lifestyle intervention had a
beneficial effect on some cardiovascular risk factors. The
intervention decreased BMI and waist circumference, and
increased exercise capacity and levels of moderate/heavy
physical activity. There was no added significant effect on
any other outcome measure.
The results achieved with this multidisciplinary struc-
tured lifestyle intervention programme of improvement
in physical activity, BMI and exercise capacity are in line
with other intensive lifestyle programmes for patients
with a history of CVD [36-38]. For instance the EURO-
ACTION preventive cardiology programme, that was
quite similar to the intervention in this study, also led to
some weight loss and for high risk patients in a reduc-
tion of central obesity. No significant effects were found
on lipid levels. The programme also improved blood
pressure control without the use of additional antihyper-
tensive drugs [9]. However in our study setting, cardio-
vascular risk management for blood pressure and lipid
Table 2 Prescribed medication at baseline and at 6-months follow-up for those who remained in the trial (n = 146)
Drug class Baseline data for those who remained in the trial Data at 6-months follow-up
Intervention
n= 59
Control
n = 60
Intervention
n= 59
Control
n = 60
Antithrombotica
Acetylsalicylic acid (aspirin) 47 (79.7%) 54 (90.0%) 49 (83.1%) 52 (86.7%)
Blood pressure-lowering medication
Angiotensin-converting enzyme (ACE inhibitors) 24 (40.7%) 21 (35.0%) 27 (45.8%) 20 (33.3%)
β-blocker 34 (57.6%) 38 (63.3%) 33 (55.9%) 40 (66.7%)
Calcium-channel blocker 12 (20.3%) 19 (31.7%) 16 (27.1%) 18 (30.0%)
Diuretica 12 (20.3%) 12 (20.0%) 12 (20.3%) 10 (16.7%)
Lipid-lowering medication
Statins 51 (86.4%) 49 (81.7%) 53 (89.8%) 54 (90.0%)
Blood glucose-lowering medicationa
Biguanides 9 (15.3%) 7 (11.7%) 10 (16.9%) 7 (11.7%)
n=number of patients; %, percentage of patients who remained in the study; adata based on diabetic patients at baseline and at 6-months follow-up.
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for CVD in usual care was close to optimal (as reflected
in baseline levels); therefore, the additional benefit of the
lifestyle intervention over usual care for blood pressure
and lipid levels was small and not significant. Even
though the smoking cessation strategy used in the
present study was evidence based, few patients ceased
smoking; this might be due to the small numbers
involved. In a Cochrane review the overall effect of psy-
chosocial smoking cessation interventions in CHD
patients was expressed by a number needed to treat of
9.7 [39]. This means that about 10 patients had to be
treated for one person to have abstained from smoking
after 1 year. Another explanation could be the relatively
high percentage of heavy smokers in our study popula-
tion. Similarly, other studies found a higher prevalence
of heavy smokers in those who continue to smoke or
who relapse after a cardiac event [40-42]. It remainsTable 3 Differences in minutes per day spent on different cat
smoking behaviour between patients in the intervention (n =
6 months follow-up
Primary outcome measure Baseline
Intervention
n= 71
Control
n =75
Physical activity SQUASH, min/week
Moderate intensity 43.9 (75.3) 33.9 (62.9)
Heavy intensity 31.0 (60.2) 30.1 (57.7)
At least moderate (moderate + heavy) 74.9 (100.3) 64.1 (85.1)
Eating behaviour DFFQ
Average vegetable intake/day, grams 172.4 (91.9) 181.9 (90.1)
Number of fruit intake/day 1.5 (1.3) 1.7 (1.2)
Number of days breakfast 6.3 (1.8) 5.5 (2.6)
* p < 0.1; **p < 0.05.unclear which method is most effective to help these
patients stop smoking [40,42].
There was no effect on estimated 10-year risk of car-
diovascular morbidity and total mortality. One reason
could be the latency of effects, i.e. benefits might not be
detected in the early stages but may emerge over time.
The present study may have been too short to show an
impact on morbidity and mortality. Another reason
could be that the individual risk assessment was per-
formed using the Copenhagen Risk Score [32]; although
this score is suitable for many of the parameters in the
present study, it does not allow input of exercise cap-
acity as an independent risk factor. The positive effect of
exercise on cardiovascular morbidity and mortality has
been well documented [43]. Myers et al. reported that
exercise capacity was a stronger predictor of mortality
than other established risk factors in men with a history
of CVD [44]. Manson et al. [45] reported that both walkingegories of physical activity (mean±SD), eating and
71) and control group (n= 75) at baseline, and at 3 and
3-months follow-up 6-months follow-up
Intergroup
differencesa B (95% CI)
p Intergroup
differencesa B (95% CI)
p
8.7 (−128.5/145.8) 0.90 187.2 (23.4/351.0)** 0.03
121.8 (−12.1/255.6)* 0.07 −4.2 (−123.0/114.6) 0.95
112.4 (−92.8/317.6) 0.3 189.6 (−1.0/380.2)** 0.05
−2.0 (−27.3/23.2) 0.98 −0.5 (−25.7/24.7) 0.97
0.03 (−0.3/0.3) 0.86 −0.05 (−0.4/0.3) 0.8
0.07 (−0.4/0.6) 0.80 0.5 (−0.1/1.1)* 0.09
Table 4 Data on mean (SD) primary outcome measures at 3 and 6-months follow-up in the intervention group (n= 71)
and control group (n= 75) and the estimated effect of the multidisciplinary lifestyle intervention on cardiovascular risk
factors compared with the control group
Primary outcome measure Baseline Baseline to 3 months 6 months
Intervention,
n = 71 mean (SD)
Control,
n = 75 mean (SD)
Intergroup
differencesa B (95% CI)
p Intergroup
differencesa B (95% CI)
p
Weight, kg 86.0 (15.0) 88.0 (20.6) −1.3 (−2.2/-0.4)** b 0.004 −1.3 (−2.5/-0.1)**b 0.03
Body mass index, kg/m2 28.7 (4.4) 29.8 (5.4) −0.5 (−0.8/-0.2)** b 0.002 −0.5 (−0.9/-0.1)**b 0.02
Waist circumference, cm 101.2 (13.4) 101.0 (14.7) −2.5 (−4.0/-1.0)** 0.001 −0.2 (−2.0/1.6)** 0.82
Systolic BP, mmHg 137.8 (20.5) 140.0 (18.2) −3.6 (−7.9/0.7) 0.10 −2.7 (−8.0/2.5) 0.30
Diastolic BP, mmHg 80.2 (10.1) 79.3 (10.5) −1.7 (−4.0/0.6) 0.15 −1.0 (−3.9/1.8) 0.47
Total cholesterol, mmol/l 4.2 (0.8) 4.6 (1.1) −0.1 (−0.3/0.2) 0.55 −0.2 (−0.5/0.1) 0.25
HDL cholesterol, mmol/l 1.3 (0.3) 1.4 (0.4) 0.02 (−0.1/0.1) 0.68 −0.0001 (−0.1/0.1) 0.99
Cholesterol/HDL ratio 3.3 (0.9) 3.4 (1.1) 0.06 (−0.2/0.3) 0.61 −0.1 (−0.4/0.2) 0.58
LDL cholesterol, mmol/l 2.2 (0.8) 2.4 (1.0) 0.001 (−0.2/0.2) 0.99 −0.1 (−0.3/0.2) 0.61
HbA1c,%
1 7.1 (1.8) 7.1 (1.3) −0.3 (−0.9/0.4) 0.38 −0.5 (−1.2/0.2) 0.14
Maximal work rate,Watt 146.1 (43.5) 156.4 (49.4) 6.9 (0.9/13.0)** 0.03 n.a.
Maximal ergometry, METS 6.4 (1.6) 6.7 (1.8) 0.3 (0.1/0.5)** 0.01 n.a.
aAdjusted for age, sex, baseline value of outcome measure and bif appropriate also adjusted for smoking; B-values reflect differences between groups over time
from baseline. CI = confidence interval; BP = blood pressure; HDL = ‘high density lipoprotein’; LDL = ‘low density lipoprotein’; HbA1c = glycolysed haemoglobin; n.a. =
not applicable.
1only among patients with diabetes mellitus type 2; **p < 0.05.
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http://www.biomedcentral.com/1471-2261/12/71and vigorous exercise are associated with substantial
reductions in the incidence of cardiovascular events irre-
spective of age and body mass index. Thus, in the present
study, the calculated risk score probably underestimated
the protective effect of the lifestyle intervention.Methodological limitations
The strength of the study is its randomised design which
reduces the chance of confounding.Table 5 Effect of the multidisciplinary structured lifestyle inte
events, general health and quality of life among patients wit
at baseline, and at 3 and 6 months
Secondary outcome measures Baseline
Intervention
n=71
Control
n = 75
I
d
10-year risk cardiovascular eventa
Coronary heart disease 37.3 (20.3) 33.8 (18.8) −
Myocardial infarction 18.9 (13.9) 17.1 (11.6) −
Cerebrovascular accident 8.2 (8.0) 7.3 (6.1) −
Total mortality 35.0 (18.1) 34.1 (17.1) 0
General health and quality of life
SF-36 MCS 52.9 (9.8) 52.2 (11.0) 0
PCS 39.6 (10.6) 42.2 (9.5) 1
MacNew b 5.3 (0.8) 5.2 (0.9) 0
Vascuqol c 4.8 (1.4) 5.6 (0.9) −
Numbers are mean (SD) unless stated otherwise; 95% CI= 95% confidence interval;
Composite Score; aUsing the PRECARDW-riskscore24; btotal score only among cardioA limitation is that all patients were receiving cardio-
vascular medication at baseline, and medication use for
patients that successively altered their lifestyle was not
lowered. Therefore, we could not prove the additional
benefit of the intervention over usual care for blood
pressure and lipid levels. However, nowadays it is not
feasible to recruit patients with established CVD that are
not on cardiovascular medication and (of course) it is
unethical to stop providing such medication to patients
randomised to the intervention group.rvention on estimated 10-year risk of cardiovascular
h stable cardiovascular disease compared with usual care
3 months 6 months
ntergroup
ifferencesa B (95% CI)
p Intergroup
differencesa B (95% CI)
p
0.6 (−3.4/2.2) 0.67 −0.6 (−4.3/3.1) 0.75
1.1 (−3.0/0.9) 0.29 −0.8 (−3.5/1.8) 0.53
0.5 (−1.5/0.4) 0.26 −0.3 (−1.4/0.9) 0.66
.2 (−2.6/3.0) 0.89 1.1 (−1.6/3.8) 0.43
.6 (−1.6/2.9) 0.58 −0.8 (−3.1/1.5) 0.50
.6 (−1.0/4.1) 0.23 1.0 (−1.7/3.7) 0.47
.06 (−0.1/0.3) 0.56 0.04 (−0.2/0.2) 0.69
0.09 (−0.9/0.7) 0.81 −0.2 (−1.7/1.3) 0.78
MCS=, norm-based Mental Composite Score; PCS=norm-based Physical
logy patients; ctotal score only among vascular patients.
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http://www.biomedcentral.com/1471-2261/12/71A potential limitation of the external validity of this
study is the non-response of patients eligible to partici-
pate. Participants were higher educated, slightly younger,
and more often still at work compared with non-respon-
ders. Also, patients participating in a trial may be more
amenable to behavioural change than those declining
participation. Therefore, our conclusions may not apply
to patients with a lower education level or those less
motivated to change their lifestyle.
In this study we had problems with the recruitment of
patients. The main reason was that eligible patients
refused to participate. Low participation rates for sec-
ondary prevention programmes have been reported re-
peatedly [46]. Another reason was the lack of financial
resources. During the recruitment period of the study
there was a change in policy of the health insurance
companies. Consequently, the intervention was no
longer reimbursed for patients and we had to stop re-
cruitment. A post-hoc power calculation showed that we
were still able to assess the effectiveness of the
programme on clinical outcomes.
The present findings may have implications for policy
on preventive cardiology for patients with established
CVD and for future research.
First, the results show that the benefits of lifestyle
intervention are sustained in the present era of wide-
spread cardiovascular therapy. Moreover, there is a
growing population of overweight, obese and physically
inactive CVD patients [10]. These trends cannot be ef-
fectively targeted with medication alone and this trial
confirms the benefits of lifestyle modification on these
risk factors. Our results are an encouraging sign that
preventive cardiology can be further improved. An eco-
nomic evaluation is needed to determine the cost-
effectiveness of the intervention.
Current evidence shows the benefits of a wide variety
of secondary prevention programmes including less in-
tensive and shorter versions [4,47]. In the Netherlands
distances to clinics are relatively short. For many coun-
tries and rural areas less intensive interventions may be
a good alternative, because they are easily accessible and
less costly. However, this may not extend to a clinically
more complicated older, fragile population that tends to
be more complex in terms of co-morbidities and treat-
ment regimen. They may need close supervision [3]. Fu-
ture research should investigate the effectiveness and
cost-effectiveness of less intensive interventions com-
pared with more intensive interventions.
Second, we recommend that future strategies for cardio-
vascular risk reduction should begin with lifestyle modifi-
cation and introduce or lower prophylactic cardiovascular
medication later on if required. Lifestyle modifications
avoid the adverse effects associated with medication and
are less costly than long-term medication.Third, a large trial is needed to compare usual care
with an intervention aimed at lifestyle modifications to-
gether with the active lowering of medication.
Conclusions
Even in CVD patients receiving good clinical care
and using cardioprotective drug treatment, a compre-
hensive lifestyle intervention had a beneficial effect
on some cardiovascular risk factors. In the present
era of cardiovascular therapy and with the increasing
numbers of overweight and physically inactive
patients, this study confirms the importance of risk
factor control through lifestyle modification as a sup-
plement to more intensified drug treatment in
patients with CVD.
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